Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Recovery 43% Improvement Relative Risk Recovery time 15% Viral clearance, day 14 5% primary Viral clearance, day 7 3% Ivermectin  Manomaipiboon et al.  EARLY TREATMENT  DB RCT Is early treatment with ivermectin beneficial for COVID-19? Double-blind RCT 72 patients in Thailand (October - December 2021) Improved recovery with ivermectin (not stat. sig., p=0.26) Manomaipiboon et al., Trials, February 2022 Favors ivermectin Favors control

Efficacy and safety of ivermectin in the treatment of mild-to-moderate COVID-19 infection: A randomized, double blind, placebo, controlled trial

Manomaipiboon et al., Trials, doi:10.1186/s13063-022-06649-3 (date from preprint), NCT05076253
Feb 2022  
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Small RCT with 72 low-risk patients in Thailand, showing improved recovery with ivermectin, without statistical significance. All patients recovered and there was no escalation of care in either group. There were no adverse events.
This is the 33rd of 47 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.0000002.
This is the 78th of 100 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
risk of no recovery, 43.5% lower, RR 0.57, p = 0.26, treatment 3 of 36 (8.3%), control 6 of 36 (16.7%), NNT 12, adjusted per study, odds ratio converted to relative risk, resolution of symptoms, Table S2, day 28.
recovery time, 15.3% lower, RR 0.85, p = 0.56, treatment 36, control 36, inverted to make RR<1 favor treatment, time to resolution of symptoms.
risk of no viral clearance, 5.0% lower, RR 0.95, p = 1.00, treatment 19 of 36 (52.8%), control 20 of 36 (55.6%), NNT 36, day 14, primary outcome.
risk of no viral clearance, 3.3% lower, RR 0.97, p = 1.00, treatment 29 of 36 (80.6%), control 30 of 36 (83.3%), NNT 36, day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Manomaipiboon et al., 2 Feb 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Thailand, peer-reviewed, mean age 48.6, 8 authors, study period 10 October, 2021 - 15 December, 2021, dosage 12mg days 1-5, trial NCT05076253 (history). Contact: (corresponding author).
This PaperIvermectinAll
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
Anan Manomaipiboon, Kittisak Pholtawornkulchai, Sujaree Poopipatpab, Swangjit Suraamornkul, Jakravoot Maneerit, Wiroj Ruksakul, Uraporn Phumisantiphong, Thananda Trakarnvanich
Trials, doi:10.1186/s13063-022-06649-3
Background: The emergent outbreak of coronavirus disease , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for therapeutic opportunities to overcome this pandemic. Ivermectin is an antiparasitic drug that has shown effectiveness against various agents, including SARS-CoV-2. This study aimed to assess the efficacy of ivermectin treatment compared with the standard of care (SOC) among people with mild to moderate COVID-19 symptoms. Methods: In this randomized, double-blind, placebo-controlled, single-center, parallel-arm, superiority trial among adult hospitalized patients with mild to moderate COVID-19, 72 patients (mean age 48.57 ± 14.80 years) were randomly assigned to either the ivermectin (n=36) or placebo (n=36) group, along with receiving standard care. We aimed to compare the negativity of reverse transcription polymerase chain reaction (RT-PCR) result at days 7 and 14 of enrolment as the primary outcome. The secondary outcomes were duration of hospitalization, frequency of clinical worsening, survival on day 28, and adverse events. Results: At days 7 and 14, no differences were observed in the proportion of PCR-positive patients (RR 0.97 at day 7 (p=0.759) and 0.95 at day 14 (p=0.813). No significant differences were found between the groups for any of the secondary endpoints, and no adverse events were reported. Conclusion: No difference was found in the proportion of PCR-positive cases after treatment with ivermectin compared with standard care among patients with mild to moderate COVID-19 symptoms. However, early symptomatic recovery was observed without side effects. Trial registration: NCT05076253. Registered on 8 October 2021, prospectively.
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s13063-022-06649-3. Additional file 1. Authors' contributions AM: supervised the project, had full access to the data in the study, and contributed to the study design. KP: contributed to data collection and conceived and designed the study. SS: collected and interpreted the data. JM: contributed in reviewing the design of the study and acquiring the data. WR: coordinated sample collection and oversaw data collection. UP: conducted and analyzed the laboratory results. TT: designed the study, analyzed, and interpreted the data and contributed towards the writing of the manuscript. All authors approve the final version of the manuscript for submission. Declarations Ethics approval and consent to participate The study was conducted according to the guidelines of the Declaration of Helsinki and Good Clinical Practice Guidelines. The trial was approved by the Vajira Ethics Committee, approval no 171/64. Written informed consent was obtained from all subjects involved in the study. Consent for publication Consent for publication is not applicable. Competing interests The authors declare they have no competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.191
Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.191
Alam, Murshed, Ebhiuyan, Saber, Alam et al., A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline, J Bangladesh Coll Phys, doi:10.3329/jbcps.v38i0.47512
Bryant, Lawrie, Dowswell, Fordham, Mitchell et al., Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines, Am J Ther, doi:10.1097/MJT.0000000000001402
Bukhari, Asghar, Perveen, Hayat, Mangat et al., Efficacy of ivermectin in COVID-19 patients with mild to moderate disease, medRxiv, doi:10.1101/2021.02.02.21250840
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Camprubí, Almuedo-Riera, Martí-Soler, Soriano, Hurtado et al., Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients, PLoS One, doi:10.1371/journal.pone.0242184
Chaccour, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalmedicine
Chachar, Khan, Asif, Tanveer, Khaqan et al., Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, Int J Sci
Chen, Kubo, Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin, J Physiol, doi:10.1113/JP275236
Choudhary, Sharma, Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance, New Microbes New Infect, doi:10.1016/j.nmni.2020.100684
Cortegiani, Ippolito, Greco, Granone, Protti et al., Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review, Pulmonology, doi:10.1016/j.pulmoe.2020.07.003
Formiga, Leblanc, De Souza Rebouças, Farias, De Oliveira et al., Ivermectin: an award-winning drug with expected antiviral activity against COVID-19, J Control Release, doi:10.1016/j.jconrel.2020.10.009
Galan, Santos, Asato, Araújo, De Lima Moreira et al., Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection, Pathog Glob Health, doi:10.1080/20477724.2021.1890887
Hashim, Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq, doi:10.1101/2020.10.26.20219345
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z
Khan, Khan, Debnath, Nath, Mahtab et al., Ivermectin treatment may improve the prognosis of patients with COVID-19, Arch Bronconeumol, doi:10.1016/j.arbres.2020.08.007
Kim, Shin, How to do random allocation (randomization), Clin Orthop Surg, doi:10.4055/cios.2014.6.1.103
Kory, Gu, Varon, Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19, Am J Ther
Mahmud, Rahman, Alam, Ahmed, Kabir et al., Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, J Int Med Res, doi:10.1177/03000605211013550
Nurullah, Demirtürk, Çetinkaya, Güner, Avcı et al., Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infect Dis, doi:10.1186/s12879-021-06104-9
Omura, Crump, Ivermectin: panacea for resource-poor communities?, Trends Parasitol, doi:10.1016/
Popp, Stegemann, Metzendorf, Gould, Kranke et al., Ivermectin for preventing and treating COVID-19, Cochrane Database Syst Rev, doi:10.1002/14651858.CD015017.pub2
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study, Chest, doi:10.1016/j.chest.2020.10.009
Ravikirti, Pattadar, Raj, Agarwal, Biswas, Ivermectin as a potential treatment for mild to moderate COVID-19 -a double blind randomized placebo-controlled trial, medRxiv, doi:10.1101/2021.01.05.21249310
Roman, Burela, Pasupuleti, Piscoya, Vidal et al., Ivermectin for the treatment of COVID-19: a systematic review and metaanalysis of randomized controlled trials, Clin Infect Dis, doi:10.1093/cid/ciab591
Shahbaznejad, Davoudi, Eslami, Markowitz, Navaeifar et al., Effects of ivermectin in patients with COVID-19: a multicenter, double-blind, randomized, controlled clinical trial, Clin Ther, doi:10.1016/j.clinthera.2021.04.007
Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Res, doi:10.1016/j.antiviral.2020.104760
Zu, Jiang, Xu, Ni, Lu et al., Coronavirus Disease 2019 (COVID-19): A Perspective from China, Radiology, doi:10.1148/radiol.2020200490
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop